Previous 10 | Next 10 |
home / stock / soltf / soltf news
Sosei Group press release (OTCPK:SOLTF): Q1 GAAP EPS of -¥25.39. Revenue of $9.6M (+433.3% Y/Y). For further details see: Sosei Group GAAP EPS of -¥25.39, revenue of $9.6M
Sosei Group Corporation (OTCPK:SOLTF) and Twist Bioscience (NASDAQ:TWST) announced a strategic partnership to identify therapeutic antibodies against G protein-coupled receptors (GPCR). Per the terms, Sosei Heptares’ proprietary StaR (stabilized receptor) platform technology will be us...
Sosei Group (SOLTF) and InveniAI, a global leader in pioneering the application of artificial intelligence and machine learning to transform innovation across drug discovery and development, announced the initiation of a new R&D collaboration.This will combine InveniAI's AI-powered p...
Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials - Dosing of first subject in clinical trial by Pfizer triggers US$5 million payment to Sosei Heptares - Third candidate nom...
Sosei Group (SOLTF): Q1 Net loss of $10.9MRevenue of $11.4M (+6.5% Y/Y) misses by $1.04M.Press Release For further details see: Sosei Group misses on revenue
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled proteins (GPCRs) C...
The following slide deck was published by Sosei Group Corporation in conjunction with this event. For further details see: Sosei Group Corporation (SOLTF) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target - Collaboration combines Sosei Heptares' leading structure-based drug design platform with PharmEnable's advanced artificial intelligence-enabled and medici...
AbbVie (ABBV) has notified Sosei Group Corporation (SOLTF) that it will return the worldwide rights to its muscarinic agonist programs. In 2016, the program was licensed by Sosei to Allergan, which was later acquired by Abbvie.As part of the process, Sosei will regain all ...
Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs PR Newswire TOKYO and CAMBRIDGE, England , Jan. 5, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it is to regain the worldwide rights to i...
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on Friday, 9 August 2024. The Company will host a live webinar presentation with C...
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million...
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance (ESG) Report for the year ended 31 December 2023. The Annu...